|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0028953,
umls-concept:C0030705,
umls-concept:C0086418,
umls-concept:C0205179,
umls-concept:C0280100,
umls-concept:C0574032,
umls-concept:C0796640,
umls-concept:C0920321,
umls-concept:C1414121,
umls-concept:C1442162,
umls-concept:C1550718,
umls-concept:C1999216
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2009-5-1
|
|
pubmed:abstractText |
To assess the safety and tolerability, pharmacokinetics, and early evidence of antitumor activity of escalating doses of MG98, an antisense oligonucleotide to DNA methyltransferase 1 (DNMT1), which has been shown to reduce CpG island methylation and allow reexpression of tumor suppressor genes in vitro.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BestermanJeffrey MJM,
pubmed-author:BoddyAlan VAV,
pubmed-author:CalvertHilaryH,
pubmed-author:ChenEric XEX,
pubmed-author:CoulthardSallyS,
pubmed-author:GriffinMelanieM,
pubmed-author:JudsonIanI,
pubmed-author:LeeChooiC,
pubmed-author:LesleyMarkM,
pubmed-author:McLeodA RobertAR,
pubmed-author:OzaAmit MAM,
pubmed-author:PlummerRuthR,
pubmed-author:ReidGregory KGK,
pubmed-author:SiuLillian LLL,
pubmed-author:SluddenJulieannJ,
pubmed-author:VidalLauraL,
pubmed-author:de BonoJohannJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3177-83
|
|
pubmed:meshHeading |
pubmed-meshheading:19383817-Adult,
pubmed-meshheading:19383817-Aged,
pubmed-meshheading:19383817-Antineoplastic Agents,
pubmed-meshheading:19383817-Cohort Studies,
pubmed-meshheading:19383817-DNA (Cytosine-5-)-Methyltransferase,
pubmed-meshheading:19383817-DNA Methylation,
pubmed-meshheading:19383817-Enzyme Inhibitors,
pubmed-meshheading:19383817-Female,
pubmed-meshheading:19383817-Humans,
pubmed-meshheading:19383817-Infusions, Intravenous,
pubmed-meshheading:19383817-Male,
pubmed-meshheading:19383817-Maximum Tolerated Dose,
pubmed-meshheading:19383817-Middle Aged,
pubmed-meshheading:19383817-Neoplasm Staging,
pubmed-meshheading:19383817-Neoplasms,
pubmed-meshheading:19383817-Oligodeoxyribonucleotides,
pubmed-meshheading:19383817-Prognosis,
pubmed-meshheading:19383817-Thionucleotides,
pubmed-meshheading:19383817-Tissue Distribution,
pubmed-meshheading:19383817-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
|
|
pubmed:affiliation |
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK. Ruth.plummer@ncl.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
